About Bronchiectasis (NCFBE) Pulmonary Medicine Intelligence Zone

Program Medium

Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period December 12, 2025 December 12, 2027, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view the activity, totaling XX hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity

XX hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.

Course Overview

In this web-based program, physicians will learn how recent developments in novel targets and treatments have advanced the management of non-cystic fibrosis bronchiectasis (NCFBE)

Release Date

December 12, 2025

Expiration Date

December 12, 2027

Intended Audience

This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with NCFBE, including pulmonary medicine and infectious disease specialists, and related clinicians.

Registration

Participation in this activity is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

This activity is supported by an independent medical education grant from Insmed.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Chan Medical School and CMEducation Resources, LLC. The University of Massachusetts Chan Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Chan Medical School, Office of Continuing Medical Education designates this enduring material for a maximum of XX AMA PRA Category 1 Credits(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Chan Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Chan Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

Professor James Chalmers Professor (Clinical), Molecular and Clinical Medicine
School of Medicine
University of Dundee School of Medicine
Dundee, Scotland, United Kingdom
Research grants or consulting fees: Astrazeneca, Boehringer Ingelheim, Chiesi, Gilead Sciences, Grifols, Insmed, Janssen, Novartis, Zambon

Prof. Francesco Blasi, MD, FERS
Professor of Respiratory Medicine
Department of Pathophysiology and Transplantation,
Vice Rector for Relations with the National Health Service
University of Milan
Dean of the School of Medicine, University of Milan
Milan, Italy
Grants, Speaker Fees and Conferences: AstrraZeneca, Chiesi, Gilead, GSK, Grifols, Guidotti-Malesci, Insmed, Menari, Novartis, Pfizer, Sanofi, Viatris, Vertex and Zambon
Consulting: AstraZeneca, Chiesi, GSK, Manri

Professor David E. Griffith, MD
Professor of Medicine
National Jewish Health
Denver, Colorado, USA
Consultant, Contracted Research and Speaker: Insmed

Professor Michael Loebinger, MA, FRCP, PhD
Director of the Lung Division, Clinical Director of Laboratory Medicine, Deputy Medical Director, Consultant Respiratory Medicine,
Royal Brompton & Harefield Hospitals
Professor of Practice (Respiratory Medicine),
National Heart and Lung Institute
Imperial College London
London, United Kingdom
Received consultancy and/or lecture fees from Insmed, Grifols, AstraZeneca, Armata, and Chiesi over past 3 years

Anne E. O’Donnell MD
The Nehemiah and Naomi Cohen Chair in Pulmonary Disease Research
Professor of Medicine
Interim Chair, Department of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Georgetown University Medical Center/Medstar Georgetown University Hospital
Washington, DC, USA
Consultant: Electromed, Insmed, Merck, Astra Zeneca
Principal Investigator (Georgetown University):Insmed, Zambon, Johnson and Johnson, Paratek, Redhill

Professor Kevin Winthrop, MD, MPH
Professor of Infectious Diseases, Ophthalmology,
Professor of Public Health and Preventive Medicine (joint appointment),
Division of Infectious Diseases, OHSU
Oregon Health and Sciences University
Portland, Oregon, USA
Research funding from NIH, PCORI, Insmed
Scientific consultant work for Bayer, Insmed
Data safety monitoring boards for RCTs conducted by UCB, Roche, Astellas, Lilly, Janssen, Galapagos, Gilead

Program Managers and Web Editor Disclosure

Program Managers Gideon Bosker, MD and Denise Leary have nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

Discuss the epidemiology, unmet therapeutic needs, global demographics, and disease burden for NCFBE based on regional and global prevalence, susceptible populations, and strategies for early confirmation of the diagnosis of NCFBE
Outline the risk factors, early clinical clues, and clinical presentation of NCFBE in a wide range of patient with predisposing risk factors
Review and apply International Guidelines—ERS, ATS, ARA, BTS, etc.—for managing NCFBE lung disease
Implement patient-centric, self-care measures that ensure recognition of disease exacerbation and that improve regimen adherence and completion of treatments deployed for NCBE
Describe the pathobiology of NCFBE, especially the role of neutrophils as cellular triggers and maintenance of pathoinflammatory changes and pathways that are responsible for progressive lung tissue destruction and that predispose to recurrent exacerbations of NCFBE
Explain the mechanistic role of neutrophil serine proteases (NSPs) as mediators of inflammation in NCFBE and the associated role of inhibition of DPP-1 to mitigate neutrophil-mediated patho-inflammatory changes that are responsible for progressive lung tissue destruction and acute changes that predispose to exacerbations of NCFBE;
Outline the role, design, implications and potential translational applications of landmark clinical trials evaluating the safety, efficacy, dosing, and clinical outcomes in patients with NCFBE who have been treated with novel, investigational agents targeting DPP-1 as a primary mechanism for reducing activity levels of NSPs and mitigating other patho-inflammatory changes mediated by neutrophils in the setting of NCFBE

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

ACCESS RESOURCES AND TRIALS
IN BRONCHIECTASIS

ABOUT THIS PROGRAM AND FACULTY DISCLOSURES